AI assistant
Verona Pharma plc — Director's Dealing 2022
May 6, 2022
30667_dirs_2022-05-05_ef7baaaf-e6a2-4038-bf7a-3c8557ce3e63.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2022-05-03
Reporting Person: ZACCARDELLI DAVID (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-03 | Ordinary Shares | S | 32904 | $0.4956 | Disposed | 16351328 | Direct |
Footnotes
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.
F3: The price reported represents the sale price of the ADSs divided by eight (8).
F4: Consists of (i) 8,342,256 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,042,782 ADSs); and (ii) 8,009,072 Ordinary Shares underlying 1,001,134 ADSs.